Loading patent…
AssigneeHuman Genome Sciences, Inc.
InventorsLuisa Iruela-Arispe, Gregg A. Hastings, Steven M. Ruben, Zdenka L. Jonak, Stephen H. Trulli, James A. Fornwald, Jonathan A. Terrett
Estimating the term…
The present invention relates to novel anti-angiogenic proteins, related to thrombospondin. More specifically, isolated nucleic acid molecules are provided encoding human METH1 and METH2. METH1 and METH2 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for the prognosis of cancer and therapeutic methods for treating individuals in need of an increased amount of METH1 or METH2. Also provided are methods for inhibiting angiogenesis using METH1 or METH2.
A method for treating an individual, comprising administering an effective amount of METH1 or METH2, wherein said method is used to treat benign tumors, an ocular angiogenic disease, vasculogenesis, granulations, hypertrophic scars, nonunion fractures, scleroderma, trachoma, vascular adhesions, myocardial angiogenesis, coronary collaterals, cerebral collaterals, arteriovenous malformations, ischemic limb angiogenesis, Osler-Webber Syndrom, plaque neovascularization, hemophiliac joints, angiofibroma, fibromuscular dysplasia, wound granulation, or atherosclerosis.
A method for treating an individual, comprising administering an effective amount of METH1 or METH2, wherein said method is used in birth control.
Dependencies are inferred from the claim text.